Global Radiotherapy Market is expected to reach USD 9.3 billion by 2024 from USD 5.2 billion in 2016, at a CAGR of 7.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.Beam radiotherapy market has the largest market segment in radiotherapy market.

Access Full Report:

The global radiotherapy market is highly concentrated to a big player and rest to local players who cater to domestic markets only. Varian Medical Systems, Inc. dominated the radiotherapy market accounting for a highest market share in 2016. Other players in this market include Elekta AB, Accuray, Inc., CIVCO Medical Solutions, Brainlab AG, C. R. Bard, Inc., IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, PRECISIS AG, Mevion Medical Systems, Inc., TechnicasRadiofiscas S.L., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, ProNova Solutions, LLC, ProTom International.Major Players In This Market Include CIVCO Medical Solutions, Brainlab AG, Among OthersVarian Medical Systems, Inc.:

Founded in 1948 as Varian Medical Systems, Inc. and head quartered in California, U.S. is a provider of radiotherapy, proton therapy and brachytherapy. Varian also supplies X-ray imaging components for medical, scientific, cargo screening and industrial applications. Varian operates through two business segments: oncology systems and imaging components.

Recent Developments:

  1. In October 2016,Varian Medical Systems, Inc. and McKesson Specialty Health announced a strategic agreement for the distribution and servicing of Varian advanced radiotherapy equipment and software over a three period across "The US Oncology Network" and "Vantage Oncology" affiliated sites of care.
  2. In October 2016,VarianMedical Systems, Inc. announced the launch of first of its kind 360 Oncology care management platform, the first software system designed to integrate and coordinate key elements of cancer so patients and their cancer teams can collaborate on achieving the best outcomes.

Elekta AB:

Founded in 1972 and headquartered in Stockholm, Swedenby LarsLeksell and Laurent Leksell.Elekta is a provider of human care, which specialises in the treatment of cancers and brain disorders. It provides oncologists, radiation therapists, neurosurgeons, and other medical specialists with the aid of clinical solutions and tools.

Recent Developments:

  1. In December 2016, Elekta, Stockholm's County Council and New KarolinskaSolna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research and education and training within advanced radiation therapy.

  1. In March 2016, Elekta announced the strategic partnership with Genesis carewhere, the later will acquire Elekta’sLeksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centres in Australia, the UK and new markets.


Accuray, Inc. is the premier radiation oncology company which develops, manufactures and sells personalized treatment solutions such as the cyberKnife and tomotherapy systems, which are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The cyberKnife system is designed to combine continual image guidance technology with a compact linear accelerator, or linac, which has the ability to move in three dimensions according to the treatment plan. The tomotherapy system operates on a ring gantry and combines integrated computed tomography, or CT, imaging with intensity modulated radiation therapy, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. Accuray was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Recent Developments:

  1. In August 2016, Accuray announced the CE approval of Radixact Treatment Delivery System, Accuray Precision Treatment Planning System and iDMS Data Management System in Europe.
  2. In June 2016, Accuray Incorporated announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.